ClinicalTrials.gg
Not yet recruitingNCT07807514Updated Sep 8, 2026

Chest X-Ray Versus Lung Ultrasound in Neonatal Pneumonia

An observational study in Neonatal Pneumonia, Respiratory Distress Syndrome and Pneumonia Neonatal, sponsored by Assiut University. Not yet recruiting. Open to participants aged 1 Minute to 28 Days. Per ClinicalTrials.gov, last updated 2026-09-08.

Sponsored by Assiut University · Observational

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
100
Ages
1 Minute to 28 Days
Sex
All
01

Study summary

This prospective observational study aims to compare the diagnostic accuracy of chest X-ray versus lung ultrasound in the diagnosis of neonatal pneumonia among neonates admitted to the Neonatal Intensive Care Unit of Assiut University Children's Hospital.

Read the detailed description

Neonatal pneumonia is a leading cause of respiratory morbidity and mortality in the neonatal period. Chest X-ray has traditionally been the reference imaging modality, but it involves ionizing radiation and has moderate sensitivity. Lung ultrasound is a radiation-free, bedside alternative that has shown promising diagnostic performance.

This prospective study will include term and preterm neonates admitted to the NICU with clinical suspicion of pneumonia within the first 28 days of life. All participants will undergo both portable chest X-ray and standardized lung ultrasound performed by trained examiners blinded to each other's findings. Diagnostic accuracy of both modalities will be compared against a composite clinical reference standard.

02

Conditions studied

  • Neonatal Pneumonia
  • Respiratory Distress Syndrome
  • Pneumonia Neonatal

Keywords

  • Point-of-care ultrasound
  • Diagnostic accuracy
  • Chest X-ray
  • Lung ultrasound
  • Neonatal pneumonia
03

In context

Respiratory Distress Syndrome

1,387 studies on the registry are indexed under Respiratory Distress Syndrome; 282 are open to participants now.

This study's planned enrollment of 100 is close to the median of 100 across 475 observational studies indexed under Respiratory Distress Syndrome.

Browse Respiratory Distress Syndrome studies →

Lead sponsor

Assiut University is the lead sponsor of 5,081 studies on the registry; 2,179 are open to participants now.

Of its 14 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
1 Minute to 28 Days
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Term and preterm neonates admitted to the Neonatal Intensive Care Unit of Assiut University Children's Hospital with clinical diagnosis of pneumonia within the first 28 days of life.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • - Neonates (term and preterm) admitted to the NICU
  • Clinical diagnosis of pneumonia within the first 28 days of life
  • Written from parents or legal guardians

Exclusion criteria

Exclusion Criteria:

  • - Major congenital pulmonary or cardiac structural malformations that would confound imaging interpretation
  • Lethal congenital anomalies or chromosomal abnormalities incompatible with survival
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
100 participants (estimated)
Target follow-up
1 Day
Patient registry
Yes

Groups and cohorts

  • Single cohort: Neonates with clinical suspicion of pneumonia

    Term and preterm neonates admitted to the NICU with clinical signs suggestive of pneumonia who will undergo both chest X-ray and lung ultrasound for diagnostic comparison.

06

What researchers measure

Primary outcomes

  1. Diagnostic accuracy of lung ultrasound versus chest X-ray

    Sensitivity, specificity, positive predictive value, and negative predictive value of lung ultrasound compared with chest X-ray for the diagnosis of neonatal pneumonia, using a composite clinical reference standard.

    Time frame: At the time of clinical suspicion of pneumonia (Baseline)

Secondary outcomes

  1. Comparison of radiographic and sonographic findings

    Description and comparison of chest X-ray findings (opacities, air bronchograms, pleural effusion) and lung ultrasound findings (subpleural consolidation, dynamic air bronchograms, B-lines, pleural line abnormalities).

    Time frame: Baseline

  2. Correlation with clinical severity

    Correlation between chest X-ray grading and lung ultrasound scores with clinical severity indices of neonatal respiratory distress (oxygenation index, FiO2 requirement, respiratory support level).

    Time frame: Baseline

  3. Risk factors associated with neonatal pneumonia

    Antenatal, perinatal, and postnatal risk factors associated with the diagnosis of neonatal pneumonia.

    Time frame: Baseline

07

Study locations

No study locations are listed for this record.

08

References and documents

Publications

  • Duda JP, Love GD, Rogov VI, Melnik DS, Blumenberg M, Grazhdankin DV. Understanding the geobiology of the terminal Ediacaran Khatyspyt Lagerstatte (Arctic Siberia, Russia). Geobiology. 2020 Nov;18(6):643-662. doi: 10.1111/gbi.12412. Epub 2020 Sep 3. PubMed 32881267 ↗
  • Batts KP, Atwaibi M, Weinberg DI, McCabe RP. Significance of serrated epithelial change in inflammatory bowel disease. Postgrad Med. 2021 Jan;133(1):66-70. doi: 10.1080/00325481.2020.1802138. Epub 2020 Sep 29. PubMed 32746680 ↗
  • Shi X, Qin Z, Liang Z, Meng D, Li J, Zhang S, Dai R, Hou E, Xin W, Liu H, Xu H, Liu Y. Polarization-selective absorptive and transmissive metamaterials. Opt Express. 2022 Jun 6;30(12):20532-20542. doi: 10.1364/OE.456849. PubMed 36224795 ↗
  • Piazza V, Gambardella C, Costa E, Miroglio R, Faimali M, Garaventa F. Cold storage effects on lethal and sublethal responses of Amphibalanus amphitrite Nauplii. Ecotoxicology. 2022 Sep;31(7):1078-1086. doi: 10.1007/s10646-022-02571-1. Epub 2022 Jul 15. PubMed 35838933 ↗
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Sep 2026; primary completion for Sep 2027, 12 months later.

Of 225 non-industry observational studies under Respiratory Distress Syndrome, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 47. This study's planned 12 months is below that.

Counting every sponsor, half of 231 studies reached it within 24 months; a quarter within 12 and three quarters within 49.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 2, 2026
First posted
Sep 8, 2026
StartEst.
Sep 2, 2026
Primary completionEst.
Sep 25, 2027
CompletionEst.
Jul 20, 2028
Last update
Sep 8, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 8, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07807514
Lead sponsor
Assiut University
Responsible party
Rana Hosny Rayan Manaa (Resident Physician, Assiut University) — Principal investigator
First posted
Sep 8, 2026
Start date
Sep 2, 2026 (estimated)
Primary completion
Sep 25, 2027 (estimated)
Completion
Jul 20, 2028 (estimated)
Last update
Sep 8, 2026

Study contacts

Rana H Rayan, Resident
Contact
Rana.18313199@med.aun.edu.eg
+20 10 69579624
Khaled A Sanousy, prof
study chair · Pediatrics Department, Assiut University Hospitals

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion